Ghulam Rehman Mohyuddin
Rating: 5.0 of 5
( out of 184 reviews )

Ghulam Rehman Mohyuddin, MBBS

Languages spoken: Hindi, English, Urdu, Pushto

Clinical Locations

Primary Location

Huntsman Cancer Institute - Cancer Research North

Clinic 2D/E, BMT/Hematology
2000 Circle of Hope
Salt Lake City , UT 84112
Get Directions

  • Dr. Mohyuddin completed his medical training at the prestigious Aga Khan University in Pakistan. He completed his internal medicine residency at the University of Kansas where he developed a passion for medical education and treating hematological malignancies. He completed his fellowship at the University of Kansas, developing a clinical and research interest in multiple myeloma, drug repurposing, quality of scientific methods, end of life, cost-effective/evidence-based care and medical education. He enjoys the outdoors tremendously, and that drew him to life in Utah where he is currently an Assistant Professor at the Huntsman Cancer Institute with a focus on multiple myeloma. His clinical interests focus on the treatment of multiple myeloma and other plasma cell dyscrasias. His specific research interests include the design and quality of clinical trials in MM, medical education, high-value care, and risk adapted/personalized therapies for patients with plasma cell dycrasias. His work has been published in high impact medical journals and he has designed numerous innovative trials to further high-value care, and improve quality of life for patients with myeloma and its precursor conditions.

    Specialties

    Board Certification

    American Board of Internal Medicine (Dual Sub: Hematology and Medical Oncology)
    American Board of Internal Medicine (Internal Medicine)

    Patient Rating

    Rating: 5.0 out of 5
    5.0 /5
    ( out of 184 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety. For the convenience of our visitors, some patient comments have been translated from their original language into English while preserving their original meaning as accurately as possible. Patients are de-identified for confidentiality and patient privacy.

    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    Dr. Mohy Ud Din is a consummate professional. I have been very impressed with his thorough and thoughtful approach to myeloma and precursor conditions. As a high-risk smoldering myeloma patient, I feel very grateful to have care provided by an expert in the field who is a specialist and conducts research in this exact disease. I ask loads of questions and read dozens of study summaries, attend on-line seminars, etc. Dr. Manni has been able to respond to all of my questions in a thought and well-reasoned manner. He has read every study I have asked about and is able to compare and contrast the varied recommendations for treatment. I cannot say enough good about him and his team and, again, feel very grateful to be a patient in their exceptional care.

    HUNTSMAN CANCER CENTER
    Rating: 3 out of 5

    Takes the time is thorough very caring

    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    Dr Mohy-ud-din explained everything very well. He explained possible treatments, and recommended the one he thought would be most beneficial at this time.

    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    Very positive and encouraging, even though some results are troubling. Has a very good way of explaining things clearly in a way that I can understand.

    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    Very professional and knowledgeable and keeps you informed about your treatment .

    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    Dr Manni is very courteous and listens well to answer all of my questions and concerns. I appreciate him and the staff for the level of care they provide.

    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    He is the top of the line when it comes to cancer care. The best thing we did for my husband was switch to Huntsman and Dr Moody Ud Din. My husband is in remission now.

    Huntsman Cancer Institute
    Rating: 5 out of 5

    He is an amazing Dr. I have 2 rare diseases and he has done so much to figure out treatment.

    HUNTSMAN CANCER CENTER
    Rating: 5 out of 5

    Kind and compassionate.

  • Dr. Mohyuddin completed his medical training at the prestigious Aga Khan University in Pakistan. He completed his internal medicine residency at the University of Kansas where he developed a passion for medical education and treating hematological malignancies. He completed his fellowship at the University of Kansas, developing a clinical and research interest in multiple myeloma, drug repurposing, quality of scientific methods, end of life, cost-effective/evidence-based care and medical education. He enjoys the outdoors tremendously, and that drew him to life in Utah where he is currently an Assistant Professor at the Huntsman Cancer Institute with a focus on multiple myeloma. His clinical interests focus on the treatment of multiple myeloma and other plasma cell dyscrasias. His specific research interests include the design and quality of clinical trials in MM, medical education, high-value care, and risk adapted/personalized therapies for patients with plasma cell dycrasias. His work has been published in high impact medical journals and he has designed numerous innovative trials to further high-value care, and improve quality of life for patients with myeloma and its precursor conditions.

    Board Certification and Academic Information

    Academic Departments Internal Medicine -Assistant Professor (Clinical)
    Academic Divisions Hematology & Hematologic Malignancies
    Board Certification
    American Board of Internal Medicine (Dual Sub: Hematology and Medical Oncology)
    American Board of Internal Medicine (Internal Medicine)

    Education history

    Professional Medical Medicine, Surgery - Aga Khan University, Medical College M.B.B.S.
    Residency Internal Medicine Categorical Residency - University of Kansas Medical Center Resident
    Chief Resident Internal Medicine - University of Kansas Medical Center Chief Resident
    Fellowship Hematology-Oncology - University of Kansas Medical Center Fellow

    Selected Publications

    Journal Article

    1. Mohyuddin GR, Clark AE, Roller J, Shune L, Lin T, Dunavin N, Dias A, Ganguly S, Abhyankar S, McGuirk J, Singh A (2018). Utility of Routine Surveillance Imaging for Hodgkin Disease following Autologous Transplant: Experiences from a Single Institution. Acta Haematol, 139(1), 52-57. (Read full publication)
    2. Mohyuddin GR, Uy J, Medhavi H, Faisal MS, Qazilbash MH (2017). Immune-Mediated Neuropathies following Autologous Stem Cell Transplantation for Multiple Myeloma: Case Series and Review of the Literature. Acta Haematol, 137(2), 86-88. (Read full publication)
    3. Mohyuddin GR, Koehn K, Abdallah AO, W Sborov D, Rajkumar SV, Kumar S, McClune B (2021). Use of endpoints in multiple myeloma randomized controlled trials over the last 15¿years: A systematic review. Am J Hematol, 96(6), 690-697. (Read full publication)
    4. Mohyuddin GR, Dominick A, Black T, Hoffman M, Male H, Byrd K, McClune B, Eck L, Neupane P (2020). A Critical Appraisal and Targeted Intervention of the Oncology Experience in an Internal Medicine Residency.(Epub ahead of print). J Cancer Educ. (Read full publication)
    5. Mohyuddin GR, Koehn K, Shune L, Aziz M, Abdallah AO, McClune B, Ganguly S, McGuirk J, Kambhampati S (2021). Renal insufficiency in multiple myeloma: a systematic review and meta-analysis of all randomized trials from 2005-2019. Leuk Lymphoma, 62(6), 1386-1395. (Read full publication)
    6. Mohyuddin GR, Al Asad M, Scratchko L, Khaleeq G (2013). Acute generalized exanthematous pustulosis with multiple organ dysfunction syndrome. Am J Crit Care, 22(3), 270-3. (Read full publication)
    7. Mohyuddin GR, Abbasi S, Okoniewski M, McClune B, Abdallah AO, Ganguly S, McGuirk J, Shune L (2020). Inpatient mortality of patients with multiple myeloma and renal impairment undergoing autologous stem cell transplantation. Eur J Haematol, 105(5), 571-577. (Read full publication)
    8. Mohyuddin GR, Aziz M, McClune B, Abdallah AO, Qazilbash M (2020). Antibiotic prophylaxis for patients with newly diagnosed multiple myeloma: Systematic review and meta-analysis. Eur J Haematol, 104(5), 420-426. (Read full publication)
    9. Pennipede D, Mohyuddin GR, Hawkins R, Ganguly S, Shune L, Ahmed N, Mohan M, Cui W, Mahmoudjafari Z, McGuirk J, Atrash S, Abdallah AO (2021). Carfilzomib, Cyclophosphamide, and Dexamethasone (KCd) for the Treatment of Triple-class Relapsed/Refractory Multiple Myeloma (RRMM).(Epub ahead of print). Eur J Haematol. (Read full publication)
    10. Ferguson JE, Vetos D, Ho BV, Aziz M, Lee WM, Mohyuddin GR, Prouty M (2021). Trends in diversity of participants in dermatology clinical trials over time: A systematic review.(Epub ahead of print). J Am Acad Dermatol. (Read full publication)
    11. Britt A, Mohyuddin GR, McClune B, Singh A, Lin T, Ganguly S, Abhyankar S, Shune L, McGuirk J, Skikne B, Godwin A, Pessetto Z, Golem S, Divine C, Dias A (2020). Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation. Leuk Res, 95, 106402. (Read full publication)
    12. Britt A, Mohyuddin GR, Al-Rajabi R (2020). Maintenance of Stable Disease in Metastatic Perivascular Epithelioid Cell Tumor of the Liver With Single-Agent Sorafenib.(Epub ahead of print). Am J Ther. (Read full publication)
    13. Dominick A, Mohyuddin GR, Fields-Meehan J, Mathur (2020). Combination Immunotherapy Associated With Severe Hepatotoxicity and Fatal Aplastic Anemia. American journal of therapeutics, (Read full publication)
    14. Mohyuddin GR, Aziz M, Britt A, Wade L, Sun W, Baranda J, Al-Rajabi R, Saeed A, Kasi (2020). Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic versus Germline BRCA mutations: a Meta-analysis and systematic review. BMC cancer, 20(1), 507. (Read full publication)
    15. Balmaceda N, Aziz M, Chandrasekar VT, McClune B, Kambhampati S, Shune L, Abdallah AO, Anwer F, Majeed A, Qazilbash M, Ganguly S, McGuirk J, Mohyuddin G (2021). Infection risks in multiple myeloma: a systematic review and meta-analysis of randomized trials from 2015 to 2019. BMC cancer, 21(1), 730. (Read full publication)
    16. Abbasi S, Roller J, Abdallah AO, Shune L, McClune B, Sborov D, Mohyuddin G (2021). Hospitalization at the end of life in patients with multiple myeloma. BMC cancer, 21(1), 339. (Read full publication)
    17. Mohyuddin GR, Alam Z, Malik UZ, Shakil O, ul Haq (2015). REVISED TRAUMA SCORE AS A PREDICTOR OF OUTCOME IN TRAUMA CASES: EXPERIENCES AT A TERTIARY CARE HOSPITAL IN KARACHI, PAKISTAN. Journal of Ayub Medical College, Abbottabad, 27(3), 584-6. (Read full publication)
    18. Parkash O, Mohyuddin GR, Ayub A, Nazir I, Maan AA, Hamid (2016). Electrophysiological changes in patients with liver cirrhosis in a tertiary care hospital in Karachi, Pakistan. Journal of Ayub Medical College, Abbottabad, 28(4), 676-679. (Read full publication)
    19. Mohyuddin GR, Romanelli N, Shune L, Abhyankar S, Ganguly S, McGuirk J, Singh (2019). Autologous hematopoietic stem cell transplant is safe for elderly lymphoma patients. Hematology/oncology and stem cell therapy, 12(2), 124-125. (Read full publication)
    20. Mohyuddin GR, Clark AE, Roller J, Shune L, Lin T, Dunavin N, Dias A, Ganguly S, Abhyankar S, McGuirk J, Singh (2018). Utility of routine surveillance imaging for diffuse large B-cell lymphoma post autologous transplant: A single center experience. Hematology/oncology and stem cell therapy, 11(3), 135-141. (Read full publication)
    21. Abdallah AO, Sigle M, Mohyuddin GR, Coggins E, Remker C, Shune L, Mahmoudjafari Z, McGuirk J, Ganguly (2021). Outcomes of VD-PACE With Immunomodulatory Agent as a Salvage Therapy for Relapsed/Refractory Multiple Myeloma. Clinical lymphoma, myeloma & leukemia, 21(2), e220-e226. (Read full publication)
    22. Abdallah AO, Mohyuddin GR, Mahmoudjafari Z, Atrash S, Kawsar H, Sigle M, Shune L, McGuirk J, Ganguly (2021). Outcomes of Daratumumab, Pomalidomide, and Dexamethasone, Followed by High-dose Chemotherapy and Autologous Stem Cell Transplantation, in Patients With Relapsed/Refractory Multiple Myeloma. Clinical lymphoma, myeloma & leukemia, 21(2), e212-e219. (Read full publication)
    23. Mohyuddin GR, Hampton J, Aziz M, Khuder S, Malik S, McClune B, Abdallah A (2021). A Systematic Review and Network Meta-analysis of Randomized Data on Efficacy of Novel Therapy Combinations in Patients with Lenalidomide-refractory Multiple Myeloma. Clinical lymphoma, myeloma & leukemia, 21(7), 489-496. (Read full publication)
    24. Gaudel P, Mohyuddin GR, Fields-Meehan (2021). Nivolumab Use for First-Line Management of Hepatocellular Carcinoma: Results of a Real-World Cohort of Patients. Federal practitioner, 38(2), 89-91. (Read full publication)
    25. Mohyuddin GR, Jobe A, Thomas (2020). Does Use of High-fidelity Simulation Improve Resident Physician Competency and Comfort Identifying and Managing Bradyarrhythmias?. Cureus, 12(2), e6872. (Read full publication)
    26. Al-Kofahi M, Mohyuddin GR, Taylor ME, Eck L (2019). Reducing Resident Physician Workload to Improve Well Being. Cureus, 11(6), e5039. (Read full publication)
    27. Mohyuddin GR, Isom N, Thomas (2019). Applying the Principles of Bloom's Taxonomy to Managing Tachyarrhythmia: Results of a Tachyarrhythmia Workshop. Cureus, 11(2), e4037. (Read full publication)
    28. Mohyuddin GR, Lester K, Thomas L, Eck LM, Newman J (2021). Implementation of an Audience Response System in a Case Conference Curriculum: Results of a Placebo-Controlled Trial. Cureus, 13(2), e13512. (Read full publication)
    29. Mohyuddin GR, Koehn K, Costa L, Kumar SK, McClune (2020). Enrolment of racial minorities across 15 years of multiple myeloma randomised trials; calling on researchers to become agents of change. The Lancet. Haematology, 7(10), e704-e706. (Read full publication)
    30. Mohyuddin GR, Koehn K, Sborov D, McClune B, Abdallah AO, Goodman AM, Prasad (2021). Quality of control groups in randomised trials of multiple myeloma enrolling in the USA: a systematic review. The Lancet. Haematology, 8(4), e299-e304. (Read full publication)
    31. Mohyuddin GR, Abdallah AO, McClune (2021). Caution With Routine Use of Daratumumab for Newly Diagnosed High-Risk Multiple Myeloma. JAMA oncology, 7(4), 635. (Read full publication)
    32. Mohyuddin GR, Rooney A, Balmaceda N, Aziz M, Sborov DW, McClune B, Kumar S (2021). Chimeric antigen receptor T-cell therapy in multiple myeloma: a systematic review and meta-analysis of 950 patients. Blood advances, 5(4), 1097-1101. (Read full publication)
    33. Mohyuddin GR, Koehn K, Abdallah AO, Goodman AM, Prasad (2021). Reporting of Postprotocol Therapies and Attrition in Multiple Myeloma Randomized Clinical Trials: A Systematic Review. JAMA network open, 4(4), e218084. (Read full publication)
    34. Mohyuddin GR, Qazilbash (2018). The role of NK Cells in Multiple Myeloma.
    35. Khan C, Mohyuddin G (2013). Bone Marrow Biopsy Simulation Training for Fellows. 4(4),
    36. Mohyuddin GR, Qureshi (2012). Recommendation for use of Vitamin ‘D’ Treatment during Pregnancy. 4, 223-6.
    37. Mohyuddin GR, Banerjee R, Alam Z, Berger KE, Chakraborty (2021). Rethinking mechanisms of neurotoxicity with BCMA directed therapy .Crit Rev Oncol Hematol. 2021 Aug 27:103453. doi: 10.1016/j.critrevonc.2021.103453. Online ahead of print.PMID: 34461271 Review. Online prior to print. (2021.103453),
    38. Mohyuddin GR, Atieh T, Ahmed N, Sborov D, McClune B, Abdallah AO, Goodman AM, Aziz M, Allen I, Prasad (2021). Intention to treat versus modified intention-to-treat analysis in B-cell maturation antigen and CD19 chimeric antigen receptor trials: A systematic review and meta-analysis. 156(October 2021), 164-174.
    39. Mohyuddin GR, Mehra N, Ryll B, Prasad (2022). Control participants of randomised trials: an often forgotten, vulnerable population. The Lancet. Haematology, 9(9), e634-e636. (Read full publication)
    40. McInturf G, Younger K, Sanchez C, Walde C, Abdallah AO, Ahmed N, Shune L, Sborov DW, Godara A, McClune B, Sinclair CT, Mohyuddin G (2022). Palliative care utilization, transfusion burden, and end-of-life care for patients with multiple myeloma. European journal of haematology, 109(5), 559-565. (Read full publication)
    41. Fatoki RA, Koehn K, Kelkar A, Al Hadidi S, Mehra N, Mian H, Landgren O, Kazandjian D, Hoffman J, Sborov DW, Mohyuddin G (2022). Global Myeloma Trial Participation and Drug Access in the Era of Novel Therapies. JCO global oncology, 8, e2200119. (Read full publication)
    42. Gil K, Abbasi S, Mehta K, McClune B, Sborov D, Ahmed N, Abdallah AO, Ganguly S, McGuirk J, Shune L, Mohyuddin G (2022). Trends in Inpatient Chemotherapy Hospitalizations, Cost and Mortality for Patients with Acute Leukemias and Myeloma. Clinical hematology international, 4(1-2), 56-59. (Read full publication)
    43. Wesson W, Galate VL, Sborov DW, McClune B, Goodman AM, Gyawali B, Prasad V, Abbasi S, Mohyuddin G (2022). Characteristics of clinical trials for haematological malignancies from 2015 to 2020: A systematic review. European journal of cancer (Oxford, England, 167, 152-160. (Read full publication)
    44. Ouchveridze E, Banerjee R, Desai A, Aziz M, Lee-Smith W, Mian H, Berger K, McClune B, Sborov D, Qazilbash M, Kumar S, Mohyuddin G (2022). Financial toxicity in hematological malignancies: a systematic review. Blood cancer journal, 12(4), 74. (Read full publication)
    45. Berger K, Mohyuddin G (2022). Reporting of trials with possible detrimental overall survival: a patient advocate perspective. The Lancet. Haematology, 9(2), e94. (Read full publication)
    46. Mohyuddin GR, Mian (2022). Daratumumab in newly diagnosed MM - incorporating lessons learnt from CASSIOPEIA, MAIA and beyond. Nature reviews. Clinical oncology, 19(1), 3-4. (Read full publication)
    47. Mohyuddin GR, Atieh T, Ahmed N, Sborov D, McClune B, Abdallah AO, Goodman AM, Aziz M, Allen I, Prasad (2021). Intention to treat versus modified intention-to-treat analysis in B-cell maturation antigen and CD19 chimeric antigen receptor trials: A systematic review and meta-analysis. European journal of cancer (Oxford, England, 156, 164-174. (Read full publication)
    48. Etekal T, Koehn K, Sborov DW, McClune B, Prasad V, Haslam A, Berger K, Booth C, Al Hadidi S, Abdallah AO, Goodman A, Mohyuddin G (2022). Time-to-event surrogate end-points in multiple myeloma randomised trials from 2005 to 2019: A surrogacy analysis. British journal of haematology, 200(5), 587-594. (Read full publication)
    49. Atieh T, Atrash S, Ahmed N, Mohan M, Cui W, Shune L, Hajjar S, Mahmoudjafari Z, Quick J, Wishna A, Riffel J, McGuirk J, Mohyuddin GR, Abdallah A (2022). Belantamab in Combination with Dexamethasone in Patients with Triple-class Relapsed/Refractory Multiple Myeloma. Clinical lymphoma, myeloma & leukemia, 22(12), 912-919. (Read full publication)
    50. Vardell VA, Ermann DA, Tantravahi SK, Haaland B, McClune B, Godara A, Mohyuddin GR, Sborov D (2023). Impact of academic medical center access on outcomes in multiple myeloma. American journal of hematology, 98(1), 41-48. (Read full publication)
    51. Mohyuddin GR, Ahlstrom JM, Chmielewski CA, Sweeney NW, Molina TH, Cheung CS, Ballard EW, Seng FF, Van Oekelen O, Godara A, McClune B, Sborov (2022). A survey on the patient perspective on cure in multiple myeloma. The Lancet. Haematology, 9(10), e716-e719. (Read full publication)
    52. Mohyuddin GR,Sinnarajah A,Gayowsky A,Chan KKW,Seow H,Mian (2022). Quality of end-of-life care in multiple myeloma: A 13-year analysis of a population-based cohort in Ontario, Canada. British journal of haematology, 199(5), 688-695. (Read full publication)
    53. Mohyuddin GR,Rabinowitz (2013). A patient with chronic lymphocytic leukemia and acquired angioedema: Correlation of clinical and biochemical response to CLL therapy. Ecancermedicalscience, 7(1), (Read full publication)
    54. Sawalha L,Kelkar AH,Mohyuddin GR,Goodman AM,Gagelmann N,Al Hadidi (2023). Analysis of repeated roles in editorial boards at oncology focused journals. Journal of cancer policy, 35, (Read full publication)
    55. Mohyuddin GR,Chakraborty R,Scheffer Cliff E (2023). The promise and harms of screening for plasma cell dyscrasias. British journal of haematology, (Read full publication)
    56. Sharma N, Wayant C, Neupane K, Lenka J, Berger K, Goodman AM, Booth CM, Prasad V, Mohyuddin G (2023). Quality of content reporting on two major oncology media websites: OncLive and Targeted Oncology. Journal of cancer policy, 36, 100411. (Read full publication)
    57. Abdallah AO, Mahmoudjafari Z, Ahmed N, Cui W, Shune L, McGuirk J, Mohan M, Mohyuddin GR, Afrough A, Alkharabsheh O, Atrash (2023). Clinical efficacy of retreatment of daratumumab-based therapy (D2) in daratumumab-refractory multiple myeloma. European journal of haematology, 110(6), 626-632. (Read full publication)
    58. Bindal P, Najjar M, Koehn K, Godara A, Sborov DW, McClune B, Julian K, Wagner C, Mohyuddin G (2023). Refractoriness to last line of therapy: how often is it mandated and reported? A systematic review of randomized myeloma trials. Leukemia & lymphoma, 64(7), 1-4. (Read full publication)
    59. Tariq SM, Abdallah AO, Goodman A, Sborov D, Mohyuddin GR, Britt (2023). The Landscape of Currently Enrolling Maintenance Trials in Multiple Myeloma. Clinical hematology international, 5(2-3), 170-176. (Read full publication)
    60. Mian A,Naqvi SAA,Ayaz A,Husnain M,Aljama MA,Mohyuddin GR,Koehn K,Mohan M,Bin Riaz I,Chakraborty (2023). Incidence of second primary malignancies in patients with multiple myeloma receiving anti-CD38 monoclonal antibodies: A systematic review and meta-analysis. Leukemia research, 131, (Read full publication)
    61. Sengar M,Hopman WM,Mohyuddin GR,Goodman AM,Gyawali B,Mukherji D,Hammad N,Pramesh CS,Aggarwal A,Sullivan R,Booth C (2023). Randomised controlled trials evaluating anticancer therapies in haematological cancers: an overview of global research activity. Ecancermedicalscience, 17, (Read full publication)
    62. Mohyuddin GR,Meirson (2023). A critical appraisal of the ATLAS trial of maintenance therapy for multiple myeloma: end points, censoring and equipoise. Nature reviews. Clinical oncology, (Read full publication)
    63. Booth CM,Sengar M,Goodman A,Wilson B,Aggarwal A,Berry S,Collingridge D,Denburg A,Eisenhauer EA,Ginsburg O,Goldstein D,Gunasekera S,Hammad N,Honda K,Jackson C,Karikios D,Knopf K,Koven R,Marini BL,Maskens D,Moraes FY,Mohyuddin GR,Poudyal BS,Pramesh CS,Roitberg F,Rubagumya F,Schott S,Sirohi B,Soto-Perez-de-Celis E,Sullivan R,Tannock IF,Trapani D,Tregear M,van der Graaf W,Vanderpuye V,Gyawali (2023). Common Sense Oncology: outcomes that matter. The Lancet. Oncology, 24(8), 833-835. (Read full publication)
    64. Hentzen S,Meirson T,Koehn K,Goodman A,Chakraborty R,Sborov D,Rubinstein S,Mohyuddin G (2023). Attrition and withdrawal in multiple myeloma randomized controlled trials: A systematic review. European journal of haematology, 111(3), 491-498. (Read full publication)
    65. Mohyuddin GR,Prasad (2023). Detecting Selection Bias in Observational Studies-When Interventions Work Too Fast. JAMA internal medicine, 183(9), 897-898. (Read full publication)
    66. Cliff ERS, Mohyuddin G (2022). Overall survival as a primary end point in multiple myeloma trials. Nature reviews. Clinical oncology, 19(9), 565-566. (Read full publication)
    67. Sengar M, Hopman WM, Mohyuddin GR, Goodman AM, Gyawali B, Mukherji D, Hammad N, Pramesh CS, Aggarwal A, Sullivan R, Booth C (2023). Randomised controlled trials evaluating anticancer therapies in haematological cancers: an overview of global research activity. Ecancermedicalscience, 17, 1558. (Read full publication)
    68. Mian A, Naqvi SAA, Ayaz A, Husnain M, Aljama MA, Mohyuddin GR, Koehn K, Mohan M, Bin Riaz I, Chakraborty (2023). Incidence of second primary malignancies in patients with multiple myeloma receiving anti-CD38 monoclonal antibodies: A systematic review and meta-analysis. Leukemia research, 131, 107324. (Read full publication)
    69. Abdallah AO, Mohyuddin GR, Ahmed N, Mohan M, Cui W, Shune L, Mahmoudjafari Z, McGuirk J, Ganguly S, Atrash (2021). Outcomes of VDPACE with an immunomodulatory agent as a salvage therapy in relapsed/refractory multiple myeloma with extramedullary disease. EJHaem, 2(4), 757-764. (Read full publication)
    70. McCurdy A, Seow H, Pond GP, Gayowsky A, Chakraborty R, Visram A, Kaedbey R, D'Souza A, Mohyuddin GR, Wildes TM, Fonseca R, Mian (2023). Cancer-specific mortality in multiple myeloma: a population-based retrospective cohort study. Haematologica, (Read full publication)
    71. Reynolds G, Cliff ERS, Mohyuddin GR, Popat R, Midha S, Ng Liet Hing M, Harrison SJ, Kesselheim A, Teh B (2023). Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis. Blood advances, (Read full publication)
    72. Balaban N, Mohyuddin GR, Kashi A, Massarweh A, Markel G, Bomze D, Goldstein DA, Meirson (2023). Projecting complete redaction of clinical trial protocols (RAPTURE): redacted cross sectional study. BMJ (Clinical research ed.), 383, e077329. (Read full publication)
    73. Abusamak AA, Abusamak M, Al-Abbadi M, Rayyan A, Oran O, Mohyuddin GR, Kelkar AH, Goodman AM, Chakraborty R, Cliff ERS, Al Hadidi (2023). Use of subjective minimizing language at hematology and oncology conferences: A systematic review. Journal of cancer policy, 39, 100461. (Read full publication)
    74. Mohyuddin GR, Chakraborty R, Cliff ERS, Derman B (2023). Clinician preferences on treatment of smoldering myeloma: a cross-sectional survey. EClinicalMedicine, 65, 102272. (Read full publication)
    75. Najjar M, McCarron J, Cliff ERS, Berger K, Steensma DP, Al Hadidi S, Chakraborty R, Goodman A, Anto E, Greene T, Sborov D, Mohyuddin G (2023). Adverse Event Reporting in Randomized Clinical Trials for Multiple Myeloma. JAMA network open, 6(11), e2342195. (Read full publication)
    76. Alrawabdeh J, Alzu'bi M, Alzyoud M, Odeh N, Hamadneh Y, Mian H, Mohyuddin GR, Kelkar AH, Goodman AM, Chakraborty R, Russler-Germain DA, Mehra N, Baggio D, Cliff ERS, Al Hadidi (2023). Characteristics of post hoc subgroup analyses of oncology clinical trials: a systematic review. JNCI cancer spectrum, 7(6), (Read full publication)
    77. Neupane K, Fortuna GG, Dahal R, Schmidt T, Fonseca R, Chakraborty R, Koehn KA, Mohan M, Mian H, Costa LJ, Sborov D, Mohyuddin G (2024). Alterations in chromosome 1q in multiple myeloma randomized clinical trials: a systematic review. Blood cancer journal, 14(1), 20. (Read full publication)
    78. Mian H, Seow H, Pond GR, Gayowsky A, Foley R, Balistky A, Ebraheem M, Cipkar C, Sapru H, Mohyuddin GR, Hadidi SA, Visram (2024). Treatment Pattern, Healthcare Resource Utilization and Symptom Burden Among Patients with Triple Class Exposed Multiple Myeloma: A Population-Based Cohort Study. Clinical lymphoma, myeloma & leukemia, (Read full publication)
    79. Ilerhunmwuwa NP, Abdul Khader AHS, Smith C, Cliff ERS, Booth CM, Rd EH, Aziz M, Lee-Smith W, Goodman A, Chakraborty R, Mohyuddin G (2024). Dietary interventions in cancer: a systematic review of all randomized controlled trials. Journal of the National Cancer Institute, (Read full publication)
    80. Mellgard G, Gilligan M, Cliff ERS, Bhutani D, Mohyuddin GR, Eisenberger A, Lentzsch S, Chakraborty (2024). Risk stratification models overestimate progression risk in contemporary patients with smoldering multiple myeloma. HemaSphere, 8(3), e61. (Read full publication)
    81. Mohyuddin GR, Goodman A (2024). Overtreatment of multiple myeloma and its precursor states: de-escalation is an urgent need in clinical practice and trials. Nature reviews. Clinical oncology, (Read full publication)
    82. Wagner CB, Julian K, Bryan B, Steinbach MN, Shewan S, Maxwell L, Vigil M, Mohyuddin GR, Godara A, McClune B, Galarza Fortuna G, Sborov (2024). Novel chemotherapy combination of carfilzomib with dexamethasone, cyclophosphamide, etoposide and cisplatin (K-DCEP) for the treatment of relapsed/refractory aggressive plasma cell dyscrasias. Leukemia & lymphoma, 65(9), 1-4. (Read full publication)
    83. Mohyuddin GR, Guadamuz JS, Ascha MS, Chiu BC, Patel PR, Sweiss K, Rohrer R, Sborov D, Calip G (2024). Comparison of patients with myeloma receiving zoledronic acid vs denosumab: a nationwide retrospective cohort study. Blood advances, 8(21), 5539-5541. (Read full publication)
    84. Kapur R, McCarron J, Rajeeve S, Mohyuddin G (2024). The landscape of clinical trials for heavily pretreated multiple myeloma: opportunity for more randomization?. Leukemia & lymphoma, 1-3. (Read full publication)
    85. Zhukovsky S, Cliff ERS, Mohyuddin G (2024). Should we screen for plasma cell dyscrasias in people with low bone density?. The Lancet. Haematology, 11(10), e715-e717. (Read full publication)
    86. Kakkilaya A, Trando A, Cliff ERS, Mian H, Al Hadidi S, Aziz M, Goodman AM, Jeong AR, Smith WL, Kelkar AH, Russler-Germain DA, Mehra N, Chakraborty R, Gertz MA, Mohyuddin G (2024). Evaluating early intervention in smoldering myeloma clinical trials: a systematic review. The oncologist, (Read full publication)
    87. Ebraheem MS, Chakraborty R, Rochwerg B, Visram A, Mohyuddin GR, Venner CP, Sandhu I, McCurdy A, Facon T, Mateos MV, Mian (2024). Quadruplet regimens for patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis. Blood advances, 8(23), 5993-6002. (Read full publication)
    88. Mohyuddin GR, Almasri J, Goodman A, Haslam A, Prasad (2024). The lifecycle and evolution of new regimens on the National Comprehensive Cancer Network Guidelines for newly diagnosed multiple myeloma. The oncologist, (Read full publication)
    89. Eisenhauer EA, Abdihamid O, Booth CM, Cherny N, Fojo AT, Gyawali B, Marini BL, Mohyuddin GR, Pe M, Pond GR, Soto-Perez-de-Celis E, Tannock IF, Trapani D, Tregear M, van der Graaf WTA, Wilson B (2025). Guidance for discussants of randomized cancer trials at major meetings. European journal of cancer (Oxford, England, 220, 115357. (Read full publication)
    90. Mohyuddin GR,Chakraborty R,Cliff ERS,Derman B (2023). Clinician preferences on treatment of smoldering myeloma: a cross-sectional survey. EClinicalMedicine, 65, (Read full publication)
    91. Baranda JC, Mohyuddin GR, Bur AM, Shnayder Y, Sweeney KR, Kakarala K, Prouty M, Pathak H, Puri R, Mitra A, Madan R, Forrest ML, Huang A, Weir S, Godwin AK, Alhakamy NA, Griffin JD, Berkland C (2023). A window of opportunity trial evaluating intratumoral injection of Copaxone® in patients with percutaneously accessible tumors. Translational medicine communications, 8, (Read full publication)
    92. Mohyuddin GR, Goodman A (2025). Daratumumab and missed sequencing opportunities in transplant-ineligible multiple myeloma: lessons for future trials. Nature reviews. Clinical oncology, (Read full publication)
    93. Vaquera-Alfaro HA, Nasrollahi E, Mangala YO, Russler-Germain D, Goodman A, Mohyuddin G (2025). Prevalence of medical writing in hematological malignancy review articles. BMC cancer, 25(1), 720. (Read full publication)
    94. Almasri J, Hasan B, Tarakji Z, Naffa' FW, Warner L, Mian H, Chakraborty R, Mohyuddin GR, Abdel-Rahman Z, Al Hadidi (2025). Treatment Outcomes of Multiple Myeloma in Developing Countries: A Systematic Review and Meta-Analysis. Clinical hematology international, 7(4), 1-20. (Read full publication)
    95. Bashy B, Shah D, Steensma D, Van Oekelen O, Chakraborty R, Mohyuddin G (2025). Differences in adverse events between manuscript and drug labels for myeloma T-cell-redirecting therapies. British journal of haematology, 207(4), 1659-1663. (Read full publication)
    96. Mohyuddin GR, Goodman AM, Chakraborty (2025). Contextualizing results of randomized trials in smoldering myeloma. The oncologist, 30(9), (Read full publication)
    97. Yadav K, Mohan M, Wagner C, Chakraborty R, Sborov D, Godara A, McClune B, Schinke C, Dhakal B, D'Souza A, Szabo A, Mohyuddin G (2025). Patterns of relapse in patients with multiple myeloma receiving chimeric antigen receptor T cell therapy: a multi-center analysis. Leukemia, 39(9), 2289-2291. (Read full publication)
    98. Olivier T, Smith C, Prasad V, Mohyuddin G (2025). Oncology "Me-Too" Drugs Compared With Original Drugs in Randomized Clinical Trials. JAMA internal medicine, 185(9), 1159-1162. (Read full publication)
    99. Mehra N, Neupane K, Mohyuddin GR, Plasma Cell Dyscrasias in South Asia Grou (2025). Research landscape of plasma cell disorders in South Asia: a call for collaboration. The Lancet. Haematology, 12(8), e572-e573. (Read full publication)
    100. Mohyuddin GR, Chakraborty R, Berger K, Winborg R, Barnes MS, Hurtado Martinez JA, Hydren JR, Sborov D, Godara A, McClune B, Booth CM, Cliff ER (2025). Patient Preferences on Clinical Decision Making in Multiple Myeloma. JCO oncology practice, OP2500322. (Read full publication)
    101. Chahine Z, Meirson T, Gilboa S, Mohyuddin G (2025). How the addition of selinexor/bortezomib/dexamethasone as a Category 1 recommendation may erode outcomes. The oncologist, 30(7), (Read full publication)

    Review

    1. Ouchveridze E, Berger K, Mohyuddin G (2022). Value in Myeloma Care: Myth or Reality. Current hematologic malignancy reports, 17, 206-216. (Read full publication)
    2. Wayant C, Mohyuddin GR, Prasad (2022). The accelerated approval pathway in oncology: Balancing the benefits and potential harms. Journal of cancer policy, 32, 100323. (Read full publication)
    3. Mohyuddin GR, Banerjee R, Alam Z, Berger KE, Chakraborty (2021). Rethinking mechanisms of neurotoxicity with BCMA directed therapy. Critical reviews in oncology/hematology, 166, 103453. (Read full publication)
    4. Steinbach M, Neupane K, Aziz M, Lee-Smith W, Julian K, Godara A, McClune B, Kelkar AH, Sborov D, Mohyuddin G (2023). Multiple Myeloma in Young Patients: A Scoping Review. Clinical lymphoma, myeloma & leukemia, 24(1), 15-22. (Read full publication)
    5. Beechinor RJ, Mohyuddin GR, Mitchell DE, Aaron D, Mahmoudjafari (2023). The story of the development of generic lenalidomide: How one company thwarted the Hatch-Waxman Act to generate billions of dollars in revenue. Journal of cancer policy, 38, 100446. (Read full publication)
    6. Vaquera-Alfaro HA, Gómez-De León A, Desai N, Mehra N, Mohyuddin G (2024). Transplant in myeloma: individualized approaches needed depending on context, access and biology. Bone marrow transplantation, (Read full publication)
    7. Zhukovsky S, White J, Chakraborty R, Costa LJ, Van Oekelen O, Sborov DW, Cliff ERS, Mohyuddin G (2024). Multiple myeloma clinical trials exclude patients with the highest-risk disease: a systematic review of trial exclusion criteria. Leukemia & lymphoma, 1-10. (Read full publication)
    8. Gyawali B, Eisenhauer EA, van der Graaf W, Booth CM, Cherny NI, Goodman AM, Koven R, Pe ML, Marini BL, Mohyuddin GR, Pond GR, Sengar M, Soto-Perez-de-Celis E, Trapani D, Tregear M, Wilson BE, Tannock I (2025). Common Sense Oncology principles for the design, analysis, and reporting of phase 3 randomised clinical trials. The Lancet. Oncology, 26(2), e80-e89. (Read full publication)
    9. Baysal M, Julian K, Sborov D, Godara A, McClune B, Lohr JG, Fortuna GG, Mohyuddin G (2025). The past, present, and future of myeloma staging and risk prognostication. The oncologist, 30(10), (Read full publication)
    10. Shah D, Shah V, Shah K, Shah PJ, Alsadhan M, Haslam A, Prasad V, Qazilbash MH, Chakraborty R, Mohyuddin G (2025). Therapeutic anti-cancer vaccines: a systematic review of prospective intervention trials for common hematological malignancies. EClinicalMedicine, 86, 103378. (Read full publication)

    Case Report

    1. Yacoub A, Mohyuddin GR, Nazzaro JM (2019). Bilateral subthalmic nucleus deep brain stimulation with microelectrode recordings in the setting of mild inherited hemophilia B: a case report. Int J Neurosci, 129(9), 933-935. (Read full publication)
    2. Mohyuddin GR, Sultan F, Zhang K, Khaleeq G (2013). Sulfasalazine induced lung toxicity masquerading as sarcoidosis--case report and review of the literature. Sarcoidosis Vasc Diffuse Lung Dis, 30(3), 226-30. (Read full publication)
    3. Mohyuddin G, Rabinowitz (2013). A patient with chronic lymphocytic leukemia and acquired angioedema: correlation of clinical and biochemical response to CLL therapy. Ecancermedicalscience, 7, 292. (Read full publication)
    4. Mohyuddin GR, Male H (2016). A Rare Cause of Hemophagocytic Lymphohistiocytosis: Fusobacterium Infection-A Case Report and Review of the Literature. Case reports in hematology, 2016, 4839146. (Read full publication)
    5. Mohyuddin GR, Yacoub (2016). Primary Myelofibrosis Presenting as Extramedullary Hematopoiesis in a Transplanted Liver Graft: Case Report and Review of the Literature. Case reports in hematology, 2016, 9515404. (Read full publication)
    6. Mohyuddin GR, Sultan F, Khaleeq (2012). A rare presentation of a rare disease: pulmonary lymphomatoid granulomatosis. Case reports in pulmonology, 2012, 371490. (Read full publication)
    7. Jobe AL, Ahonen KT, Poplin V, Rao S, Mohyuddin G (2018). Afatinib-induced Interstitial Lung Disease Successfully Treated with Corticosteroids: Case Report and Review of the Literature. Cureus, 10(6), e2805. (Read full publication)
    8. Moosajee SM, Mohyuddin GR, Khan S, Kamal A (2013). Acute acquired demyelinating polyneuropathy–an initial presentation of diffuse large B cell lymphoma. 4(1), 35-8.

    Editorial

    1. Mohyuddin GR, Banerjee R, Goodman A (2021). Lack of equipoise in the LIGHTHOUSE trial for patients with relapsed multiple myeloma: An ethical concern. European journal of cancer (Oxford, England, 157, 533-535. (Read full publication)
    2. Smith C, Booth CM, Mohyuddin G (2024). Dietary interventions, statistical power, and unanswered questions. Journal of the National Cancer Institute, 116(8), 1404-1405. (Read full publication)

    Letter

    1. Mohyuddin GR, Sigle M, Chandrasekar VT, Aziz M, Abdallah AO, Shune L, McClune B (2020). Impact of anti-CD38 therapy in multiple myeloma with high-risk cytogenetics: systematic review and meta-analysis. [Letter to the editor]. Leuk Lymphoma, 61(10), 2519-2522. (Read full publication)
    2. Mohyuddin GR, Abbasi S, Ripp J, Singh A, Kambhampati S, McClune B (2020). Patients with leukemia dying in the hospital: results of the national inpatient sample and a call to do better. [Letter to the editor]. Leuk Lymphoma, 61(11), 2760-2762. (Read full publication)
    3. Mohyuddin GR, Okoniewski M, Diab O, Ganguly S, Shune L, Abdallah AO, McGuirk J, McClune B (2021). Maintenance regimens after a second autologous transplant for multiple myeloma. [Letter to the editor]. Leuk Lymphoma, 62(3), 758-760. (Read full publication)
    4. Abbasi S, Britt A, McClune B, Shune L, Kambhampati S, Mohyuddin GR (2020). Inpatient hospitalization's associated cost and mortality in myeloma patients undergoing autologous stem cell transplant: a 13-year analysis of the National Inpatient Sample. [Letter to the editor]. Leuk Lymphoma, 61(5), 1254-1256. (Read full publication)
    5. Mohyuddin GR, Faisal MS, Badar T, Shah N, Bashir Q, Patel KK, Hosing C, Popat UR, Rondon G, Delgado R, Shah JJ, Weber DM, Thomas SK, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH (2018). A case control study of syngeneic transplantation versus autologous transplantation for multiple myeloma: two decades of experiences from a single center. [Letter to the editor]. Leuk Lymphoma, 59(2), 515-518. (Read full publication)
    6. Mohyuddin GR, Ouchveridze E, Goodman A, Prasad V (2021). The landscape of trials for smoldering multiple myeloma: endpoints, trial design, and lessons learnt. [Letter to the editor]. Leuk Lymphoma, 1-3. (Read full publication)
    7. Mohyuddin GR, Abdallah AO, McClune B, Goodman A, Prasad V (2021). Multiple myeloma triplet therapies: baseline characteristics and control groups. [Letter to the editor]. Lancet, 397(10285), 1620-1621. (Read full publication)
    8. Mohyuddin GR, Roller J, Shune L, Lin T, Dias A, Ganguly S, Abhyankar S, McGuirk J, Singh (2019). Epstein-Barr viremia and post-transplant lymphoproliferative disorders in patients undergoing haploidentical stem cell transplantation with post-transplant cyclophosphamide. Hematology/oncology and stem cell therapy, 12(3), 171-173. (Read full publication)
    9. Ripp J, Mohyuddin GR, Al-Jumayli M, Huang (2021). Outcomes in older patients with NSCLC receiving immunotherapy: A single center experience. Journal of geriatric oncology, (Read full publication)
    10. Goodman AM, Mohyuddin GR, Prasad (2022). Ivosidenib and Azacitidine in IDH1-Mutated AML. The New England journal of medicine, 386(26), 2536. (Read full publication)
    11. Soomro MA, Hoffman J, Goodman AM, Sborov DW, Mohyuddin G (2022). Heterogeneity of enrolment criteria for ongoing smouldering myeloma trials. British journal of haematology, 197(6), e86-e88. (Read full publication)
    12. Banerjee R, Midha S, Kelkar AH, Goodman A, Prasad V, Mohyuddin G (2022). Synthetic control arms in studies of multiple myeloma and diffuse large B-cell lymphoma. British journal of haematology, 196(5), 1274-1277. (Read full publication)
    13. Meirson T, Markel G, Prasad V, Goodman AM, Mohyuddin G (2022). Post-protocol therapy and informative censoring in the CANDOR study. The Lancet. Oncology, 23(3), e97. (Read full publication)
    14. Mohyuddin GR, Goodman AM, Knopf (2022). Perils of Ignoring Overall Survival in Interpreting the Myeloma Literature. Journal of clinical oncology, 40(1), 105-106. (Read full publication)
    15. Mohyuddin GR, Chakraborty R, Calip GS, Ascha MS, Wang X, Rubinstein SM, Tuchman S, Costa L, Haaland B, Giri S, Mian H, Fonseca R, Sborov (2022). Prognostic value of translocation 11;14 in patients with relapsed/refractory myeloma receiving anti-CD38 therapy. Blood cancer journal, 12(12), 168. (Read full publication)
    16. Van Oekelen O, Birrer N, Wesson W, Galate VL, Cliff ERS, Goodman AM, Abdallah AO, Chakraborty R, Prasad V, Mohyuddin G (2022). Characteristics of measurable residual disease assessment in myeloma: a review of clinical trials from 2015-2020. Blood cancer journal, 12(11), 155. (Read full publication)
    17. Cliff ERS,Mian H,Mohyuddin G (2022). Teclistamab in Relapsed or Refractory Multiple Myeloma. The New England journal of medicine, 387(18), 1721-1722. (Read full publication)
    18. Ouchveridze E,Booth C,Mohyuddin G (2023). Subgroups and precision in myeloma. Journal of cancer policy, 35, (Read full publication)
    19. Mohyuddin GR, Goodman A (2023). Ineligible for transplant, but eligible for intensive quadruplet therapy-The value of 'add-on' trials for vulnerable patient populations. European journal of cancer (Oxford, England, 185, 164-166. (Read full publication)
    20. Cliff ERS, Reynolds G, Popat R, Teh BW, Kesselheim AS, Mohyuddin G (2023). Acknowledging Infection Risk in Bispecific Antibody Trials in the Treatment of Multiple Myeloma. Journal of clinical oncology, 41(10), 1949-1951. (Read full publication)
    21. Mohyuddin GR, Kapur R, Costa (2023). Inclusion criteria of currently enrolling T-cell engaging trials in multiple myeloma: Should we be focusing on lines of prior therapy?. British journal of haematology, (Read full publication)
    22. Tariq SM,Abdallah AO,Goodman A,Sborov D,Mohyuddin GR,Britt (2023). The Landscape of Currently Enrolling Maintenance Trials in Multiple Myeloma. Clinical hematology international, 5(2-3), 170-176. (Read full publication)
    23. Bindal P,Najjar M,Koehn K,Godara A,Sborov DW,McClune B,Jullian K,Wagner C,Mohyuddin G (2023). Refractoriness to last line of therapy: how often is it mandated and reported? A systematic review of randomized myeloma trials. Leukemia & lymphoma, (Read full publication)
    24. Gil K,Abbasi S,Mehta K,McClune B,Sborov D,Ahmed N,Abdallah AO,Ganguly S,McGuirk J,Shune L,Mohyuddin G (2022). Trends in Inpatient Chemotherapy Hospitalizations, Cost and Mortality for Patients with Acute Leukemias and Myeloma. Clinical hematology international, 4(1-2), 56-59. (Read full publication)
    25. Chakraborty R,Hadidi SA,Scheffer Cliff ER,Mohyuddin G (2023). Is aggressive treatment of smoldering myeloma the path to curing myeloma?. Blood advances, 7(15), 3932-3935. (Read full publication)
    26. Beechinor RJ, Mahmoudjafari Z, Mohyuddin G (2023). Financial Toxicity in Oncology, More Unanswered Questions. Journal of clinical oncology, JCO2300915. (Read full publication)
    27. Gong Z, Umoru G, Monge J, Shah N, Mohyuddin GR, Radhakrishnan SV, Chakraborty R, Rasche L, Schinke C, D'Souza A, Mohan (2024). Adverse effects and non-relapse mortality of BCMA directed T cell therapies in multiple myeloma: an FAERS database study. Blood cancer journal, 14(1), 36. (Read full publication)
    28. Mohyuddin GR, Rubinstein SM, Kumar S, Rajkumar SV, Fonseca R, Abdallah NH, Calip GS, Wang X, Parrinello CM, Sborov (2024). Performance of newer myeloma staging systems in a contemporary, large patient cohort. Blood cancer journal, 14(1), 95. (Read full publication)
    29. Chakraborty R, Cheruvalath H, Patwari A, Szabo A, Schinke C, Dhakal B, Lentzsch S, D'Souza A, Mohyuddin GR, Julian K, Midha S, Costello P, Kaiser M, Hing MNL, Harrison SJ, Cliff ERS, Mohan (2024). Sustained remission following finite duration bispecific antibody therapy in patients with relapsed/refractory myeloma. Blood cancer journal, 14(1), 137. (Read full publication)
    30. Mellgard G,Gilligan M,Cliff ERS,Bhutani D,Mohyuddin GR,Eisenberger A,Lentzsch S,Chakraborty (2024). Risk stratification models overestimate progression risk in contemporary patients with smoldering multiple myeloma. HemaSphere, 8(3), (Read full publication)
    31. Mohyuddin GR,Mian H,Gayowsky A,Seow H,Chakraborty R,Pond GR,Al Hadidi S,Visram (2024). Impact of age on treatment utilization for newly diagnosed multiple myeloma: a nationwide retrospective cohort study. Blood cancer journal, 14(1), (Read full publication)
    32. Visram A,Chan KKW,Seow H,Pond G,Gayowsky A,Mohyuddin GR,McCurdy A,Sandhu I,Venner C,Lancman G,Balitsky A,Kouroukis T,Bruins R,Kumar S,Fonseca R,Mian (2025). Comparing the clinical trial efficacy versus real-world effectiveness of treatments for multiple myeloma: a population-based study. Haematologica, 110(1), 228-233. (Read full publication)
    33. Chunara F, Lugo C, Osinski K, Shah MR, Shah N, Kent J, Mohyuddin GR, Radhakrishnan SV, Kaur G, Chakraborty R, Banerjee R, Rasche L, Schinke C, D'Souza A, Szabo A, Mohan (2025). Real-world treatment patterns for teclistamab and talquetamab in multiple myeloma (MM): experience from 609 patients. Blood cancer journal, 15(1), 61. (Read full publication)

  • News & Podcasts

    Huntsman Cancer Institute News